UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2019

BioSig Technologies, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**000-55473**	**26-4333375**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

12424 Wilshire Blvd., Suite 745 **Los Angeles, California**	**90025**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(763) 999-7330**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	BSGM	The NASDAQ Capital Market

Item 8.01 Other Events.

On June 20, 2019, BioSig Technologies, Inc. (the "Company") issued a press release announcing that it has issued June 2019 Shareholder Letter. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release, dated June 20, 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSIG TECHNOLOGIES, INC.

Date: June 20, 2019

By: /s/ Kenneth L. Londoner
Name: Kenneth L. Londoner
Title: Executive Chairman

BioSig Technologies Issues June 2019 Shareholder Letter

Top Tier New Corporate Talent and First Successful Clinical Results from Leading Medical Institutions Pave Way for Commercial Rollout

Santa Monica, CA, June 20, 2019 -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has issued their June 2019 Shareholder Letter, highlighting successful patient cases using PURE EP(tm) System at three different medical centers, strengthening of patent portfolio and publication strategy, inclusion on the Russell 3000® Index, and other milestones moving toward commercialization.

Recent Company Highlights:

- Successfully conducted patient cases using PURE EP(tm) System at Indiana University School of Medicine, Texas Cardiac Arrhythmia Institute and Greenville Memorial Hospital
- Announced that the company is set to join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, 2019
- Announced that the U.S. Patent & Trademark Office allowed a U.S. patent application covering its PURE EP(tm) Simulator
- Received a total of $4.6 million in warrant and option exercises in Q1 and Q2 2019
- Announced that the U.S. Patent Office allowed 33 patent claims covering its PURE EP(tm) System.
- Announced that Jerome Zeldis, M.D., Ph.D, former Chief Medical Officer of Celgene, re-joined BioSig as an Independent Director
- BioSig's manuscript entitled, *"Evaluation of Real Time Catheter Tissue Contact using Unipolar Intracardiac Signal Morphology"* was accepted at International Engineering in Medicine and Biology Conference 2019
- Participated at the Heart Rhythm Society's 40th Annual Scientific Sessions in San Francisco, CA
- Appointed Frank J. Quintero and D.A. Wallach to Advisory Board
- Completed private placement for $8,620,506 in March 2019
- Appointed Dr. Barry Keenan, Ph.D, MBA, PMP to head up BioSig's advanced product development.

"The highlight of first five months of 2019 was, of course, the success of our first patient cases using PURE EP(tm) System at three different medical institutions," stated Mr. Kenneth Londoner, Founder, Chairman and CEO of BioSig Technologies. "BioSig attended the Heart Rhythm Society's 40th Annual Scientific Sessions and received outstanding feedback and support from the medical and scientific community. We have been working diligently towards commercialization and are excited that the PURE EP(tm) System has delivered great results during the first phase of external evaluation. Every area of our business has been solidified in the first five months of 2019 - strong balance sheet, exceptional human talent, first class clinical partners and robust intellectual property portfolio all mean that we've never been stronger as a Company. We would like to thank all our loyal shareholders – we never take your support for granted and will continue to work tirelessly on your behalf."

To view BioSig Technologies' June 2019 Shareholder Letter please visit the Company's website.

About BioSig Technologies

BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace (www.biosig.com). Led by a proven management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.

The Company's first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. BioSig's ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EP™ System in August 2018.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact:
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
12424 Wilshire Blvd Ste 745
Los Angeles, CA 90025
ndrapeau@biosigtech.com
310-620-9320